Are Drugs Made in Emerging Markets Good Quality?

One of the unwritten, unspoken and rarely thought-about assumptions of those buying medicines is that they will work. We take it for granted that the medicines we buy will work as the scientists who developed the product intended. But in many places this is not the case--especially in Africa and to a lesser extent in Asia and Latin America.

The reasons are complex, but essentially there are three types of ‘problem products’: counterfeit, substandard and degraded. Counterfeits are products which are passed off as something they are not. Substantial effort is put into creating perfect copies of real packaging, but little care is usually put into making the products properly. Such drugs are a real threat to rich and poor alike. The most widely faked drugs are Viagra, painkillers and diet pills; but increasingly drugs for many serious conditions and infections, particularly in poorer locations, are causing problems.

Substandard products are those where manufacturers are sloppy and, ignoring gross negligence, unintentionally make bad copies of drugs. This category is probably vast in poor nations. Degraded products are properly manufactured but become bad because of incorrect storage. This is a significant concern in places with no electricity for refrigeration and no cold chain transport storage. Recent research has tried to identify the causes of these problems and the extent to which they are harming people. My own research, published in Research and Reports in Tropical Medicine last December, analysed the prevalence of the problem and also which types of manufacturers were at fault. The findings are concerning, especially for African countries. Nearly 20% of the African-sourced drugs we tested failed at least one quality control test: in other words they almost certainly would not work as intended.

View the full text of this article as an Adobe Acrobat PDF

Roger Bate is the Legatum Fellow in Global Prosperity at AEI.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate
  • Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
  • Phone: 202-828-6029
    Email: rbate@aei.org
  • Assistant Info

    Name: Katherine Earle
    Phone: (202) 862-5872
    Email: katherine.earle@aei.org

What's new on AEI

image The Census Bureau and Obamacare: Dumb decision? Yes. Conspiracy? No.
image A 'three-state solution' for Middle East peace
image Give the CBO long-range tools
image The coming collapse of India's communists
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

No events scheduled today.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.